IAT: Embody Insertional Achilles Tendinopathy

Sponsor
Zimmer Biomet (Industry)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05998785
Collaborator
Embody Inc. (Industry)
15
2
28
7.5
0.3

Study Details

Study Description

Brief Summary

The primary objective of this study is to evaluate the long-term effects on ankle/Achilles tendon pain after repair of insertional Achilles tendinopathy (IAT) augmented with TAPESTRY Biointegrative Implant.

Condition or Disease Intervention/Treatment Phase
  • Device: TAPESTRY Biointegrative Implant

Detailed Description

This study is a prospective case series of patients who have had insertional Achilles tendinopathy repair augmented with the Tapestry Biointegrative Implant. The primary aim of the study is to describe patient reported pain 12 months after surgical repair with Tapestry. The secondary aims are to assess the proportion of study subjects that experience treatment-related adverse events post-surgery, treatment related serious adverse events resulting in second surgical intervention, quality of life and other patient reported outcomes at all follow up timepoints post-surgery, and tissue thickness measured with MRI at 6 months post-surgery.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
A Multi-Center, Prospective Case Series Evaluating Insertional Achilles Tendinopathy Repair Augmented With TAPESTRY® Biointegrative Implant
Actual Study Start Date :
Aug 2, 2022
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Pain/VAS [12 months post-surgery]

    Visual Analog Scale (VAS) survey

Secondary Outcome Measures

  1. Safety/Adverse Events [Surgery, 1 week, 2 weeks, 4 weeks, 6 weeks, 10 weeks, 3 months, 6 moths and 12 months post-op]

    Procedure and/or treatment related adverse events; Procedure and/or treatment related Serious Adverse Events (SAE) Procedure and/or treatment related Serious Adverse Events (SAE) necessitating a second surgical intervention (SSI);

  2. Patient Satisfaction [1 week, 2 weeks, 4 weeks, 6 weeks, 10 weeks, 3 months, 6 moths and 12 months post-op]

    Patient Satisfaction Survey

  3. Return to Normal Activity [1 week, 2 weeks, 4 weeks, 6 weeks, 10 weeks, 3 months, 6 moths and 12 months post-op]

    Return to Normal Activity survey

  4. AOFAS [Baseline, 1 week, 2 weeks, 4 weeks, 6 weeks, 10 weeks, 3 months, 6 moths and 12 months post-op]

    American Orthopedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot questionnaire

  5. SF-12 [Baseline, 1 week, 2 weeks, 4 weeks, 6 weeks, 10 weeks, 3 months, 6 moths and 12 months post-op]

    12-item Short Form- Health Survey

  6. Tissue Thickness [Baseline and 6 months post-op]

    MRI tissue thickness of the Achilles tendon at baseline and 6 months post-surgery. Tissue thickness will be measured by trained personnel per the EMBODY-002 MRI procedure manual.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult, 21 years and older;

  • Insertional Achilles tendonitis requiring surgery that has failed at least 2 weeks of conservative management, which consist of:

  1. Shoe modification; or

  2. Nonsteroidal anti-inflammatory drugs; or

  3. Physical Therapy with/without modalities.

  • Chronic Achilles tendon pain lasting longer than 3 months;

  • MRI of the ankle within 30 days prior to the study surgery;

  • Ability and willingness to comply with prescribed post-operative rehabilitation program;

  • Ability and willingness to comply with follow-up regimen;

  • Able to understand the informed consent process, including regulatory requirements such as HIPAA authorization, and document informed consent prior to completion of any study-related procedures; and

  • Ability to read, understand, and complete subject-reported outcomes in English.

Exclusion Criteria:
  • History of Achilles tendon rupture;

  • Previous Achilles tendon surgery on the index ankle;

  • Genetic collagen disease, hypersensitivity, or objection to using bovine-derived materials;

  • History of auto-immune or immunodeficiency disorders;

  • History of chronic inflammatory disorders;

  • Oral steroid use in last 2 months or injectable steroid use in last 4 weeks;

  • History of heavy smoking (> 1 pack per day) within last 6 months;

  • Hypersensitivity to poly(D,L-lactide) materials;

  • Metal implants, fillings, shrapnel, and/or screws;

  • Females of child-bearing potential who are pregnant or plan to become pregnant during the course of the study;

  • Currently involved in any injury litigation or worker's compensation claims relating to the index ankle;

  • Enrolled, or plans to enroll, in another clinical trial during this studythat would affect the outcomes of this study; or

  • History of non-compliance with medical treatment, physical therapy/rehabilitation, or clinical study participation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Weil Foot and Ankle Institute Libertyville Illinois United States 60048
2 Utica Park Clinic Tulsa Oklahoma United States 74104

Sponsors and Collaborators

  • Zimmer Biomet
  • Embody Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zimmer Biomet
ClinicalTrials.gov Identifier:
NCT05998785
Other Study ID Numbers:
  • EMBODY-002
First Posted:
Aug 21, 2023
Last Update Posted:
Aug 21, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 21, 2023